Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ: SRRK )

36.10 +1.55 (+4.50%)
Streaming Delayed Price Updated: 12:33 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Via Benzinga
How Is The Market Feeling About Scholar Rock Holding?
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
What's going on in today's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24. 
Via Benzinga
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Via Benzinga
Here's Why Everybody's Talking About Scholar Rock Right Now
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers. 
Via The Motley Fool
Nasdaq To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... 
Via Benzinga
Exposures Product Safety
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
Via Benzinga
US Stocks Open Lower; Dow Tumbles Over 150 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Constellation Energy, Nike, Sinclair And Other Big Stocks Moving Higher On Friday
Via Benzinga
SRRK Stock Earnings: Scholar Rock Holding Beats EPS for Q2 2024
SRRK stock results show that Scholar Rock Holding beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024
SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.